Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HMGCR | P04035 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.37 |
| ▸ | PGD | P52209 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.35 |
| ▸ | CPT2 | P23786 | 1/20 | 0.34 |
| ▸ | ACLY | P53396 | 1/20 | 0.34 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4313364 | 1.00 | TDP1 (0.39) | TDP1TSHRALDH1A1SMN1; SMN2HMGCR | |
| SCHEMBL1533821 | 1.00 | TDP1 (0.39) | TDP1TSHRALDH1A1SMN1; SMN2HMGCR | |
| SCHEMBL28481021 | 0.98 | TDP1 (0.37) | TDP1TSHRALDH1A1SMN1; SMN2HMGCR | |
| SCHEMBL14558024 | 0.81 | TDP1 (0.42) | TDP1TSHRALDH1A1SMN1; SMN2HMGCR | |
| SCHEMBL5929523 | 0.78 | CYP1A2 (0.45) | HSPD1BLMHSPE1FOLH1 | |
| SCHEMBL1941444 | 0.78 | TDP1 (0.43) | TDP1TSHRSMN1; SMN2HMGCRCHRM1 | |
| SCHEMBL28117913 | 0.78 | TDP1 (0.43) | TDP1TSHRSMN1; SMN2HMGCRCHRM1 | |
| SCHEMBL8853350 | 0.78 | TDP1 (0.43) | TDP1TSHRSMN1; SMN2HMGCRCHRM1 | |
| SCHEMBL1941442 | 0.78 | TDP1 (0.43) | TDP1TSHRSMN1; SMN2HMGCRCHRM1 | |
| SCHEMBL17092560 | 0.77 | LMNA (0.36) | TSHRALDH1A1HSPD1BLMHSPE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12138691-B2 | Method for the synthesis of mesoporous platinum nanoparticles in an aqueous environment | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2024-11-12 | — | — | US | claimed |
| EP-3956086-B1 | METHOD FOR THE SYNTHESIS OF MESOPOROUS PLATINUM NANOPARTICLES IN AN AQUEOUS ENVIRONMENT | FONDAZIONE ST ITALIANO TECNOLOGIA (IT) | 2023-10-18 | — | — | EP | claimed |
| CN-108430676-B | Method for synthesizing metal nanoparticles in an aqueous environment without the use of shape-directing agents | 意大利科技研究基金会 | 2021-11-02 | — | — | CN | claimed |
| US-10596632-B2 | Method for the synthesis of metal nanoparticles in aqueous environment without the use of shape directing agents | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2020-03-24 | — | — | US | claimed |
| EP-3389905-B1 | METHOD FOR THE SYNTHESIS OF METAL NANOPARTICLES IN AQUEOUS ENVIRONMENT WITHOUT THE USE OF SHAPE DIRECTING AGENTS | FONDAZIONE ST ITALIANO TECNOLOGIA (IT) | 2019-09-04 | — | — | EP | claimed |
| US-20180361482-A1 | METHOD FOR THE SYNTHESIS OF METAL NANOPARTICLES IN AQUEOUS ENVIRONMENT WITHOUT THE USE OF SHAPE DIRECTING AGENTS | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2018-12-20 | — | — | US | claimed |
| EP-3389905-A1 | METHOD FOR THE SYNTHESIS OF METAL NANOPARTICLES IN AQUEOUS ENVIRONMENT WITHOUT THE USE OF SHAPE DIRECTING AGENTS | Fondazione Istituto Italiano di Tecnologia (IT) | 2018-10-24 | — | — | EP | claimed |
| US-10064885-B2 | Metabolic gene, enzyme, and flux targets for cancer therapy | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2018-09-04 | — | — | US | claimed |
| US-20130331432-A1 | METABOLIC GENE, ENZYME, AND FLUX TARGETS FOR CANCER THERAPY | THE GENERAL HOSPITAL CORPORATION D/B/A MASSACHUSETTS GENERAL HOSPITAL (US) | 2013-12-12 | — | — | US | claimed |
| US-20130225663-A1 | LIPID DELIVERY FORMULATIONS | DICERNA PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | claimed |
| WO-2012006506-A1 | METABOLIC GENE, ENZYME, AND FLUX TARGETS FOR CANCER THERAPY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2012-01-12 | — | — | WO | claimed |
| WO-2011109294-A1 | LIPID DELIVERY FORMULATIONS | DICERNA PHARMACEUTICALS, INC. (US) | 2011-09-09 | — | — | WO | claimed |
| US-20080300208-A1 | Isociatrate dehydrogenase and uses therof | QUARK PHARMACEUTICALS, INC. | 2008-12-04 | — | — | US | claimed |
| US-20070219269-A1 | NOVEL ACONITASE | THE BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM | 2007-09-20 | — | — | US | claimed |
| US-7183100-B2 | Aconitase | BIOLOGICAL TARGETS, INC. (US) | 2007-02-27 | — | — | US | claimed |
| WO-2006022640-A1 | NOVEL ACONITASE | BIOLOGICAL TARGETS, INC. (US) | 2006-03-02 | — | — | WO | claimed |
| US-20040248276-A1 | Novel aconitase | THE BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM | 2004-12-09 | — | — | US | claimed |
| US-20040067234-A1 | Isocitrate dehydrogenase and uses thereof | QUARK PHARMACUTICALS, INC. | 2004-04-08 | — | — | US | claimed |
| US-20260035515-A1 | SURFACE ADDITIVE BASED ON POLYSILOXANE MODIFIED UNSATURATED POLYESTER | BYK CHEMIE GMBH (DE) | 2026-02-05 | — | — | US | disclosed |
| WO-1998039453-A1 | METHODS FOR THE BIOSYNTHESIS OF POLYESTERS | MONSANTO COMPANY (US) | 1998-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035515-A1 | SURFACE ADDITIVE BASED ON POLYSILOXANE MODIFIED UNSATURATED POLYESTER | SCO2, H1-0, PYM1 | TDP1 2707/4885TSHR 4179/4885ALDH1A1 1307/4885 |
| US-20040067234-A1 | Isocitrate dehydrogenase and uses thereof | IDH2, IDH1, IDH3A | TDP1 570/4885TSHR 4254/4885ALDH1A1 319/4885 |
| US-20070219269-A1 | NOVEL ACONITASE | MDH2, IDH2, IDH1 | TDP1 3077/4885TSHR 4816/4885ALDH1A1 1508/4885 |
| US-20130225663-A1 | LIPID DELIVERY FORMULATIONS | LIPA, LIPC, CETP | TDP1 4612/4885TSHR 4015/4885ALDH1A1 3881/4885 |
| US-20080300208-A1 | Isociatrate dehydrogenase and uses therof | IDH2, IDH1, IDH3A | TDP1 334/4885TSHR 4545/4885ALDH1A1 466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.